ribosomal modification protein rimK like family member BGenealiases: FAM80B · NAAGS · NAAGS-I
Q-omics provides the consensus-scored RIMKLB profile across patient tissues and cancer cell-line models. RIMKLB expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RIMKLB is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, RIMKLB RNA expression shows 20,243 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, THCA, and UVM as cancer lineages where RIMKLB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RIMKLB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RIMKLB survival associations across molecular data types. RIMKLB RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RIMKLB RNA expression–survival associations across cancer types. High RIMKLB expression shows unfavorable associations in MESO, COAD and UVM, but favorable associations in CHOL, UCS and LIHC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify MESO as the clearest survival context for RIMKLB RNA expression.
This table summarizes RIMKLB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for RIMKLB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RIMKLB shows lower tumor expression in THCA, UCEC, COAD and BRCA and higher tumor expression in HNSC and KICH. The THCA box plot shows higher RIMKLB RNA expression in normal versus tumor tissue (log2 FC = −0.782, t-test p < 0.001).
This table shows molecular features associated with RIMKLB in patient tissues and cancer cell lines. In patient samples, RIMKLB shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RIMKLB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
